GSK_ Annual_Report_2021-22

165 Notes to the Standalone Financial Statements for the year ended March 31, 2022 ( ` in lakhs) As at March 31, 2021 (t) Cross charges recoverable at the period end : GSK India Global Services Private Limited 4.82 (iv) Disclosure in respect of material transactions with persons referred to in item 1(iv) above: ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 1 Remuneration/commission/sitting fees 40,41.79 37,93.20 2 Payments under the long-term incentive plan 2,27.62 2,95.47 (v) Disclosure in respect of material transactions with persons referred to in item 1(iv) above: ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 (a) Remuneration/commission/sitting fees (Refer Note below): Mr. S. Venkatesh 9,98.38 8,21.46 Mr. A. Iyer - 3,42.86 Mr. R. Krishnaswamy - 5,01.22 Ms. P. Thakur 4,03.70 3,27.63 Ms. M. Priyam - 1,24.19 (b) Payments made during the year under the long-term incentive plan (Refer Note below): Ms. P. Thakur 85.82 27.89 Mr. R. Krishnaswamy - 53.24 Mr. S. Dheri 39.64 26.48 Mr. A. Iyer - 89.16 Mr. B. Kotak - 43.36 Note: Amounts are not comparable as they pertain to part of the year and/ or are recorded on cash payment basis.